And notice how it was presented in here. Other drugs listed by name/API in the header. IPE lumped under a generalized triglyceride lowering header. At the very end after all the high tech drugs listed. Many on here still scratch their heads wondering why Lovaza outsells V.
V is positioned right where makers of patented *mab and sRNA class drug makers paid to put them. Stuck fighting other generics at the kids table.
Indeed, IPE (VASCEPA) has the biggest price advantage among all, what it need is just HUGE volume to scale up, and that optimum volume uptake can only be achieved via a BUYOUT by a BP.
News 
Market Data 
Discover 
